Tibsovo Gets A Win In AML Following Servier Takeover

 
• By Alaric DeArment

Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.

Acute myeloid leukemia a 3d-Render
Servier announced results from the Phase III AGILE study of Tibsovo in IDH1-mutant AML • Source: Shutterstock

More from Clinical Trials

More from R&D